CLINICAL SIGNIFICANCE OF COMBINING BCR-ABL1 TRANSCRIPT LEVELS AT 3 AND 6 MONTHS IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH FRONTLINE SECOND-GENERATION TYROSINE KINASE INHIBITORS

被引：0
|
作者：
Lee, S. E. [1 ,2 ]
Choi, S. Y. [2 ]
Kim, S. H. [2 ]
Oh, Y. J. [2 ]
Chae, M. J. [2 ]
Song, H. Y. [2 ]
Yoo, H. L. [2 ]
Lee, M. Y. [2 ]
Jang, E. J. [2 ]
Jeong, K. H. [2 ]
Lee, J. S. [2 ]
Kim, D. W. [1 ,2 ]
机构：
[1] Catholic Univ Korea, Seoul St Marys Hosp, Dept Hematol, Seoul, South Korea
[2] Catholic Univ Korea, Canc Res Inst, Seoul, South Korea
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB1546
引用
收藏
页码：599 / 599
页数：1
相关论文
共 50 条
  • [41] Economic Burden of Adverse Events Among Patients with Chronic Myelogenous Leukemia Treated with BCR-ABL1 Tyrosine Kinase Inhibitors
    Lin, Jay
    Dinara, Makenbaeva
    Robyn, Bilmes
    Lingohr-Smith, Melissa
    Wallis, Nicola
    BLOOD, 2015, 126 (23)
  • [42] Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia
    Dakota Gustafson
    Jason E. Fish
    Jeffrey H. Lipton
    Nazanin Aghel
    Current Hematologic Malignancy Reports, 2020, 15 : 20 - 30
  • [43] Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia
    Gustafson, Dakota
    Fish, Jason E.
    Lipton, Jeffrey H.
    Aghel, Nazanin
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2020, 15 (01) : 20 - 30
  • [44] Impact of Second-Generation Tyrosine Kinase Inhibitors As Second Line Treatment for Patients with Chronic Myeloid Leukemia
    Valentin Garcia-Gutierrez, J.
    Herrera, Pilar
    Abalo, Lorena L.
    Dolores Rey, Maria
    Calbacho, Maria
    Ramos, Lourdes
    Ramos, Paloma
    Montalban, Carlos
    Lopez-Jimenez, Javier
    BLOOD, 2011, 118 (21) : 1615 - 1615
  • [45] BCR-ABL1 RT-qPCR for Monitoring the Molecular Response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
    Press, Richard D.
    Kamel-Reid, Suzanne
    Ang, Daphne
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2013, 15 (05): : 565 - 576
  • [46] Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: a Malaysian cohort study
    Abu Seman, Zahidah
    Ahid, Fadly
    Kamaluddin, Nor Rizan
    Sahid, Ermi Neiza Mohd
    Esa, Ezalia
    Said, Siti Shahrum Muhamed
    Azman, Norazlina
    Mat, Wan Khairull Dhalila Wan
    Abdullah, Julia
    Ali, Nurul Aqilah
    Khalid, Mohd Khairul Nizam Mohd
    Yusoff, Yuslina Mat
    BMC RESEARCH NOTES, 2024, 17 (01)
  • [47] CLINICAL SIGNIFICANCE OF EARLY MOLECULAR RESPONSES (BCR-ABL1 ≤10% AT 3 MONTHS AND ≤1% 6 MONTHS) AS A PREDICTOR FOR LONG-TERM OUTCOMES IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH IMATINIB
    Lee, S.
    Choi, S.
    Kim, S.
    Bang, J.
    Oh, Y.
    Park, J.
    Jeon, H.
    Jang, E.
    Kim, D.
    HAEMATOLOGICA, 2013, 98 : 299 - 300
  • [48] MOLECULAR RESPONSE TO THERAPY WITH TYROSINE KINASE INHIBITORS IN PATIENTS WITH BCR-ABL1(+) CHRONIC MYELOID LEUKEMIA PRESENTING WITH AN ISOLATED THROMBOCYTOSIS AT THE ONSET
    Balatzenko, G.
    Hrischev, V.
    Ignatova, K.
    Stoyanova, Z.
    Lilova, A.
    Angelova, S.
    Ivanova, S.
    Romanova, M.
    Ivanova, I.
    Tsvetkova, G.
    Hadjiev, E.
    Madzharova, V.
    Dikov, T.
    Spassov, B.
    Davidkova, Y.
    Jagurinoski, M.
    Guenova, M.
    HAEMATOLOGICA, 2017, 102 : 733 - 733
  • [49] Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase
    Sasaki, Koji
    Kantarjian, Hagop
    O'Brien, Susan
    Ravandi, Farhad
    Konopleva, Marina
    Borthakur, Gautam
    Garcia-Manero, Guillermo
    Wierda, William
    Daver, Naval
    Ferrajoli, Alessandra
    Takahashi, Koichi
    Jain, Preetesh
    Rios, Mary Beth
    Pierce, Sherry
    Jabbour, Elias
    Cortes, Jorge E.
    CANCER, 2018, 124 (06) : 1160 - 1168
  • [50] A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors
    Zulbaran-Rojas, Alejandro
    Lin, Huei-Kan
    Shi, Qiuling
    Williams, Loretta A.
    George, Binsah
    Garcia-Manero, Guillermo
    Jabbour, Elias
    O'Brien, Susan
    Ravandi, Farhad
    Wierda, William
    Estrov, Zeev
    Borthakur, Gautam
    Kadia, Tapan
    Cleeland, Charles
    Cortes, Jorge E.
    Kantarjian, Hagop
    CANCER MEDICINE, 2018, 7 (11): : 5457 - 5469
12345